{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:08:53Z","timestamp":1791493733812,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40360-017-0152-7","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T08:56:31Z","timestamp":1496825791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-na\u00efve Fabry disease patients"],"prefix":"10.1186","volume":"18","author":[{"given":"Kazuya","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"issue":"21","key":"152_CR1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, et al. Enzyme defect in Fabry\u2019s disease: Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276(21):1163\u20137.","journal-title":"N Engl J Med"},{"issue":"9","key":"152_CR2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","volume":"103","author":"A Metha","year":"2010","unstructured":"Metha A, Beck M, Eyskens F, et al. Fabry disease: a review of current management strategies. QJM. 2010;103(9):641\u201359.","journal-title":"QJM"},{"key":"152_CR3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Ohpanet J Rare Dis. 2010;5:30.","journal-title":"Ohpanet J Rare Dis"},{"issue":"5","key":"152_CR4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DDDT.S11985","volume":"14","author":"U Ramaswami","year":"2011","unstructured":"Ramaswami U. Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther. 2011;14(5):155\u201373.","journal-title":"Drug Des Devel Ther"},{"issue":"9706","key":"152_CR5","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet. 2009;374(9706):1986\u201396. Erratum in Lancet 2010; 375(9710):200.","journal-title":"Lancet"},{"key":"152_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","volume":"3","author":"M Beck","year":"2015","unstructured":"Beck M, Hughes D, Kampmann C, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry outcome survey analysis. Mol Genet Metab Rep. 2015;3:21\u20137.","journal-title":"Mol Genet Metab Rep"},{"key":"152_CR7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52:353\u20138.","journal-title":"J Med Genet"},{"key":"152_CR8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","volume":"10","author":"C Kampmann","year":"2015","unstructured":"Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease cardiac outcomes after 10\u00a0years\u2019 treatment. Orphanet J Rare Dis. 2015;10:125\u201331.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"152_CR9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","volume":"274","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Niemann M, Stork S, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease for disease progression towards serious complications. J Intern Med. 2013;274(4):331\u201341.","journal-title":"J Intern Med"},{"issue":"4","key":"152_CR10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ymgme.2012.01.010","volume":"105","author":"T Togawa","year":"2012","unstructured":"Togawa T, Tsukimura T, Kodama T, et al. Fabry disease: Biochemical, pathological and structural studies of the \u03b1-galactosidase A with E66Q amino acid substitution. Mol Genet Metab. 2012;105(4):615\u201320.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"152_CR11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","volume":"100","author":"T Togawa","year":"2010","unstructured":"Togawa T, Kodama T, Suzuki T, et al. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab. 2010;100(3):257\u201361.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"152_CR12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0885-3924(98)00098-0","volume":"16","author":"J Uki","year":"1998","unstructured":"Uki J, Mendoza T, Cleeland CS, et al. A brief cancer pain assessment tool in Japanese: the utility of the Japanese brief pain inventory -BPI-J. J Pain Symptom Manage. 1998;16(6):364\u201373.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"152_CR13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hec.673","volume":"11","author":"A Tsuchiya","year":"2002","unstructured":"Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11(4):341\u201353.","journal-title":"Health Econ"},{"issue":"4","key":"152_CR14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.krcp.2016.09.001","volume":"35","author":"Y Tomino","year":"2016","unstructured":"Tomino Y. Diagnosis and treatment of patients with IgA nephropathy in Japan. Kidney Res Clin Pract. 2016;35(4):197\u2013203.","journal-title":"Kidney Res Clin Pract"},{"issue":"21","key":"152_CR15","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u20139.","journal-title":"JAMA"},{"issue":"2","key":"152_CR16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase Alfa. Heart. 2008;94(2):153\u20138.","journal-title":"Heart"},{"issue":"10","key":"152_CR17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","volume":"97","author":"M Beer","year":"2006","unstructured":"Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry\u2019s cardiomyopathy. Am J Cardiol. 2006;97(10):1515\u20138.","journal-title":"Am J Cardiol"},{"issue":"5","key":"152_CR18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","volume":"20","author":"M West","year":"2009","unstructured":"West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol. 2009;20(5):1132\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"152_CR19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy. Evidence for a better outcome with early treatment. Circulation. 2009;119:524\u20139.","journal-title":"Circulation"},{"key":"152_CR20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","volume":"7","author":"S Feriozzi","year":"2012","unstructured":"Feriozzi S, Torras J, Cybulla M, et al. The effectiveness of long-term Agalsidase Alfa therapy in the treatment of fabry nephropathy. Clin J Am Soc Nephrol. 2012;7:60\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"152_CR21","volume-title":"Fabry disease: perspectives from 5 years of FOS","year":"2006","unstructured":"Mehta A, Beck MD, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford Pharma Genesis; 2006."},{"issue":"7","key":"152_CR22","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102\u201311.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"152_CR23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77\u201386.","journal-title":"Ann Intern Med"},{"issue":"3","key":"152_CR24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","volume":"130","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008;130(3):367\u201373.","journal-title":"Int J Cardiol"},{"issue":"5","key":"152_CR25","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jpeds.2009.11.007","volume":"156","author":"R Schiffmann","year":"2010","unstructured":"Schiffmann R, Martin RA, Reimschisel T, et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr. 2010;156(5):832\u20137.","journal-title":"J Pediatr"},{"issue":"6","key":"152_CR26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","volume":"28","author":"R Schiffmann","year":"2003","unstructured":"Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003;28(6):703\u201310.","journal-title":"Muscle Nerve"},{"issue":"4","key":"152_CR27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","volume":"28","author":"Y Eto","year":"2005","unstructured":"Eto Y, Ohashi T, Utsunomiya Y, et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis. 2005;28(4):575\u201383.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"152_CR28","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54\u00a0months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547\u201357.","journal-title":"J Am Soc Nephrol"},{"key":"152_CR29","unstructured":"Japanese packaging insert [REPLAGAL]. Version 5. Dainippon-Sumitomo Pharmaceutical company, April 2015;\nhttps:\/\/ds-pharma.jp\/product\/replagal\/pdf\/replagal_inj_tenpu.pdf\n\n."},{"issue":"2","key":"152_CR30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Rise M, Timmons M, et al. Long-Term Therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant (UK). 2006;21(2):345\u201354.","journal-title":"Nephrol Dial Transplant (UK)"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-017-0152-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T08:56:47Z","timestamp":1496825807000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-017-0152-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1186\/s40360-017-0152-7","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]},"article-number":"43"}}